Inhibition effect of nobiletin as BH3 mimetic drug on small cell lung cancer and synergistic effect of nobiletin and histone deacetylase inhibitor

Abstract

The invention provides application of nobiletin as a BH3 mimetic drug and / or a histone deacetylase inhibitor in preparation of drugs for treatment or adjuvant treatment of small cell lung cancer; or the nobiletin is used as a BH3 mimetic drug and / or a histone deacetylase inhibitor to prepare a product for inhibiting small cell lung cancer cell proliferation. Experimental results show that nobiletin shows a stronger inhibition effect on small cell lung cancer compared with non-small cell lung cancer. Moreover, according to the cell survival rate observed 24 hours after administration, the fixed vorinostat concentration is 1 [mu]M, AD23 can generate a high synergistic effect in a range of 0.1-100 [mu]M, and if the fixed AD23 is 3 [mu]M, the vorinostat has a high synergistic effect in a range of 1-30 [mu]M.

Description

technical field

[0001] The invention relates to the field of cancer research, in particular to the inhibitory effect of nobiletin as a BH3 analog drug on small cell lung cancer and its synergistic effect with histone deacetylase inhibitors. Background technique

[0002] The morbidity and mortality of lung cancer are increasing year by year worldwide, and about 85% of them are non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors (TKI) targeting epidermal growth factor receptor (EGFR) can be effectively treated For NSCLC with EGFR mutation, three generations of TKIs have been used clinically. Small cell lung cancer (SCLC) accounts for about 15% of the total number of lung cancers. It is characterized by strong invasion, early metastasis, and poor prognosis. The first-line treatment drugs are platinum and etoposide or irinotecan. Although these two types of lung cancer are sensitive to targeted drugs and chemotherapy drugs respectively, they are prone to drug resista...

Images